Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Leerink Swann lowered their FY2017 earnings per share (EPS) estimates for Alexion Pharmaceuticals in a research report issued on Monday. Leerink Swann analyst now expects that the biopharmaceutical company will post earnings per share of $5.16 for the year, down from their prior forecast of $5.17. Leerink Swann currently has a “Buy” rating and a $182.00 target price on the stock.

Other equities analysts also recently issued research reports about the stock. UBS AG reaffirmed a “buy” rating and issued a $142.00 price objective (up previously from $140.00) on shares of Alexion Pharmaceuticals in a report on Monday, June 26th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $180.00 price objective (up previously from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. BidaskClub raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. Cowen and Company reaffirmed an “outperform” rating and issued a $122.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, July 3rd. Finally, Deutsche Bank AG reaffirmed a “buy” rating and issued a $158.00 price objective (up previously from $153.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $154.56.

COPYRIGHT VIOLATION WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/18/fy2017-eps-estimates-for-alexion-pharmaceuticals-inc-alxn-reduced-by-leerink-swann.html.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 143.92 on Wednesday. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34. The stock has a market cap of $32.12 billion, a P/E ratio of 62.41 and a beta of 1.39. The company has a 50-day moving average of $142.24 and a 200 day moving average of $127.19.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm had revenue of $912.00 million during the quarter, compared to the consensus estimate of $846.15 million. During the same quarter in the prior year, the firm earned $1.13 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 21.1% on a year-over-year basis.

A number of large investors have recently added to or reduced their stakes in ALXN. BlackRock Inc. lifted its holdings in Alexion Pharmaceuticals by 2,689.8% during the 1st quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock worth $2,258,467,000 after purchasing an additional 17,960,356 shares during the last quarter. Third Point LLC acquired a new stake in Alexion Pharmaceuticals during the 2nd quarter worth approximately $152,088,000. Bank of Montreal Can lifted its holdings in Alexion Pharmaceuticals by 628.8% during the 2nd quarter. Bank of Montreal Can now owns 1,423,318 shares of the biopharmaceutical company’s stock worth $173,174,000 after purchasing an additional 1,228,025 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Alexion Pharmaceuticals by 1,697.6% during the 2nd quarter. Janus Henderson Group PLC now owns 1,145,918 shares of the biopharmaceutical company’s stock worth $139,424,000 after purchasing an additional 1,082,171 shares during the last quarter. Finally, TIAA CREF Investment Management LLC lifted its holdings in Alexion Pharmaceuticals by 42.2% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 3,219,961 shares of the biopharmaceutical company’s stock worth $391,773,000 after purchasing an additional 955,578 shares during the last quarter. 94.25% of the stock is owned by institutional investors and hedge funds.

In related news, EVP Julie O’neill sold 11,160 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now directly owns 26,704 shares of the company’s stock, valued at approximately $3,738,560. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ann M. Veneman sold 835 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the sale, the director now directly owns 5,480 shares of the company’s stock, valued at $799,038.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,190 shares of company stock valued at $2,433,669. Insiders own 4.35% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.